Veloxis Pharmaceuticals announces financial results for the first quarter 2012 ... Sacramento Bee The primary endpoint of the study, a composite endpoint (biopsy proven acute rejection, graft failure, loss to follow up or death), will be evaluated after a 12-month treatment period to demonstrate the non-inferiority of LCP-Tacro™ compared to ... |
